randomized trial of PAdriaCEBO versus PMitCEBO patients older than 60 with high-grade lymphoma: results of a BNLI Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for

http://bloodjournal.hematologylibrary.org/cgi/content/full/97/10/2991 Updated information and services can be found at: (4075 articles) Neoplasia • (2398 articles) Clinical Trials and Observations • collections: Blood Articles on similar topics may be found in the following http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl Information about subscriptions and ASH membership may be found online at:

[1]  G. Dukart,et al.  Mitoxantrone: an overview of safety and toxicity , 2004, Investigational New Drugs.

[2]  M. Rikkert,et al.  Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions , 1999, Cancer.

[3]  M. Hidalgo,et al.  Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Coiffier,et al.  A multivariate analysis of the survival of patients with aggressive lymphoma , 1998 .

[5]  B. Coiffier,et al.  A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. , 1998, Cancer.

[6]  Daniel S. Miller,et al.  Cancer incidence and mortality, 1973‐1995 , 1998 .

[7]  E. Iannitto,et al.  Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. , 1998, Haematologica.

[8]  W. Gianni,et al.  Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions , 1998, Cancer.

[9]  A. Glass,et al.  The national cancer data base report on non‐hodgkin's lymphoma , 1997, Cancer.

[10]  E. Salminen.  Age-Related Survival in Non-Hodgkin’s Lymphoma , 1997, Oncology.

[11]  D. Dorfman,et al.  Non‐Hodgkin's lymphomas: Current classification and management , 1997, CA: a cancer journal for clinicians.

[12]  J. Connors,et al.  Treatment considerations in the elderly patient with lymphoma. , 1997, Hematology/oncology clinics of North America.

[13]  J. Blay,et al.  Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Kimmick,et al.  Cancer Chemotherapy in Older Adults , 1997, Drugs & aging.

[15]  T. Petrella,et al.  Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Inbar,et al.  Prognostic importance of advanced age in aggressive non-Hodgkin's malignant lymphoma. , 1996, Oncology.

[17]  J. Jager,et al.  Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Levis,et al.  The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. , 1996, Leukemia & lymphoma.

[19]  K. Maclennan,et al.  A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. , 1996, British Journal of Cancer.

[20]  G. Longo,et al.  A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly. , 1996, Leukemia & lymphoma.

[21]  W Hop,et al.  Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Ho,et al.  Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas , 1995 .

[23]  D. Faraggi,et al.  Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. , 1995, Acta oncologica.

[24]  W. Bezwoda,et al.  Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. , 1995, European journal of cancer.

[25]  J. Hainsworth,et al.  Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide. , 1994, Journal of the National Cancer Institute.

[26]  E. Franssen,et al.  Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. Ellis,et al.  Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology. , 1994, European journal of cancer.

[28]  B. Coiffier.  What treatment for elderly patients with aggressive lymphoma? , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Fisher,et al.  A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Weisenburger.  Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Crowther,et al.  Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Petrini,et al.  Alternating chemotherapy regimen (P‐VABEC) for intermediate and high‐grade non‐Hodgkin's lymphoma of the middle aged and elderly , 1994, Hematological oncology.

[33]  F. Mandelli,et al.  P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Connors,et al.  In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Gherlinzoni,et al.  VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. , 1993, Haematologica.

[36]  P. Goss.  Non-Hodgkin's lymphomas in elderly patients. , 1993, Leukemia & lymphoma.

[37]  S. Ansell,et al.  A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma. , 1993, Annals of Oncology.

[38]  V. Chiarion-Sileni,et al.  A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  F. d'Amore,et al.  Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  A. Erazo,et al.  Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  R. Talamini,et al.  A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Ansell,et al.  Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  B. Coiffier,et al.  Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: A phase II study , 2006, Hematological oncology.

[44]  S. Monfardini,et al.  Common errors in conducting and reporting clinical trials in non-Hodgkin lymphomas and patients' age. , 1991, European Journal of Cancer.

[45]  T. Miller,et al.  Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Connors,et al.  Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Hainsworth,et al.  A brief‐duration combination chemotherapy for elderly patients with poor‐prognosis non‐Hodgkin's lymphoma , 1991, Cancer.

[48]  W. Hryniuk,et al.  The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  F. Takaku,et al.  Pirarubicin, A Novel Derivative of Doxorubicin THP‐COP Therapy for Non‐Hodgkin's Lymphoma in the Elderly , 1990, American journal of clinical oncology.

[50]  D Faraggi,et al.  Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables , 1990, Cancer.

[51]  P. Sonneveld,et al.  Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. , 1990, British Journal of Cancer.

[52]  U. Schuler,et al.  Pharmacokinetics and Metabolism of Mitoxantrone A Review , 1990, Clinical pharmacokinetics.

[53]  J. Green,et al.  Non-Hodgkin's lymphoma. A four-drug regimen suitable for elderly patients with advanced disease. , 1990, Acta oncologica.

[54]  S. Monfardini,et al.  Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. , 1990, Cancer investigation.

[55]  F. Gherlinzoni,et al.  A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. , 1989, Haematologica.

[56]  D. Weisenburger,et al.  The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  U. Vitolo,et al.  CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. , 1988, Haematologica.

[58]  P. Gaulard,et al.  Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. , 1987, The American journal of medicine.

[59]  V. Zagonel,et al.  Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. , 1987, European journal of cancer & clinical oncology.

[60]  R. Gams,et al.  Mitoxantrone in malignant lymphoma. , 1985, Investigational new drugs.

[61]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.

[62]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[63]  F. Yates.  Contingency Tables Involving Small Numbers and the χ2 Test , 1934 .

[64]  Daan Brandenbarg.  The National. , 1892 .

[65]  D.,et al.  Regression Models and Life-Tables , 2022 .